Across TCGA pan-cancer cohorts, CYB5RL Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CYB5RL data layer compared with 21 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher CYB5RL Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CYB5RL expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

DLBC, COAD, and SKCM are the cancer types where CYB5RL Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	OS	Median	II,III,IV	0.172	0.949	<.001	30	view →
COAD	OS	Median	All	0.111	0.871	<.001	12	view →
SKCM	DFS	Median	All	0.558	0.193	.031	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: CYB5RL tumor-vs-normal RNA expression · all CYB5RL data types